Incyte Stops Development Of HIV Treatment

Incyte Corp. (INCY) halted development of its HIV treatment DFC after patients in a midstage clinical trial experienced increased incidences of pancreatic inflammation. Shares of the pharmaceutical company plunged $2.44 to close at $3.58.